Sol-Gel Technologies (SLGL) Cash & Equivalents (2016 - 2025)
Sol-Gel Technologies (SLGL) reported Cash & Equivalents of $11.0 million for Q4 2025, down 43.39% year-over-year from $19.5 million in Q4 2024, and up 64.55% on a QoQ basis from $6.7 million in Q3 2025.
Sol-Gel Technologies (SLGL) has 10 years of Cash & Equivalents data on file, last reported at $11.0 million in Q4 2025.
- Quarterly Cash & Equivalents fell 43.39% year-over-year to $11.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.0 million (down 43.39% YoY) and the FY2025 annual result came in at $11.0 million, down 43.39% from the prior year.
- Cash & Equivalents rose to $11.0 million in Q4 2025 per SLGL's latest filing, from $6.7 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $43.3 million in Q3 2021 and bottomed at $5.8 million in Q2 2022.
- The 5-year median for Cash & Equivalents is $12.0 million (2022), against an average of $14.0 million.
- The widest annual swing landed in 2021, when Cash & Equivalents soared 621.64%; it then sank 80.39% in 2022.
- Tracing SLGL's Cash & Equivalents over 5 years: stood at $20.1 million in 2021, then plunged by 38.02% to $12.4 million in 2022, then slumped by 39.64% to $7.5 million in 2023, then soared by 159.4% to $19.5 million in 2024, then slumped by 43.39% to $11.0 million in 2025.
- Per Business Quant, the three latest SLGL Cash & Equivalents figures stand at $11.0 million (Q4 2025), $6.7 million (Q3 2025), and $10.2 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Sol-Gel Technologies | 205.76 Mn | 194.73 Mn | - | 11.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.03 Mn |
| Sep 30, 2025 | 6.71 Mn |
| Jun 30, 2025 | 10.22 Mn |
| Mar 31, 2025 | 16.89 Mn |
| Dec 31, 2024 | 19.49 Mn |
| Sep 30, 2024 | 13.42 Mn |
| Jun 30, 2024 | 11.55 Mn |
| Mar 31, 2024 | 11.21 Mn |
| Dec 31, 2023 | 7.51 Mn |
| Sep 30, 2023 | 14.14 Mn |
| Jun 30, 2023 | 15.62 Mn |
| Mar 31, 2023 | 6.81 Mn |
| Dec 31, 2022 | 12.45 Mn |
| Sep 30, 2022 | 8.50 Mn |
| Jun 30, 2022 | 5.77 Mn |
| Mar 31, 2022 | 21.25 Mn |
| Dec 31, 2021 | 20.09 Mn |
| Sep 30, 2021 | 43.35 Mn |
| Jun 30, 2021 | 11.15 Mn |
| Mar 31, 2021 | 12.65 Mn |
| Dec 31, 2020 | 7.12 Mn |
| Sep 30, 2020 | 6.01 Mn |
| Jun 30, 2020 | 5.44 Mn |
| Mar 31, 2020 | 2.20 Mn |
| Dec 31, 2019 | 9.41 Mn |
| Sep 30, 2019 | 7.64 Mn |
| Jun 30, 2019 | 14.39 Mn |
| Mar 31, 2019 | 8.18 Mn |
| Dec 31, 2018 | 5.33 Mn |
| Sep 30, 2018 | 13.27 Mn |
| Jun 30, 2018 | 18.24 Mn |
| Mar 31, 2018 | 79.80 Mn |
| Dec 31, 2017 | 5.02 Mn |
| Dec 31, 2016 | 7.00 Mn |